Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8ZXT6)

• Drug Name: Oxymetazoline Drug Info
• Synonyms: Hazol; Iliadin; Nafrine; Navasin; Navisin; Nezeril; Oximetazolina; Oximetazolinum; Oxylazine; Oxymetazolinum; Oxymethazoline; Oxymetozoline; Rhinofrenol; Rhinolitan; Sinerol; Dristan Long Lasting Mentholated Nasal Spray; Dristan Long Lasting Nasal Mist; Drixoral Nasal Solution; Oxymeta zoline; Oxymetazoline hydrochloride crystalline; Afrin Cherry 12 Hour Nasal Spray; Afrin Extra Moisturizing 12 Hour Nasal Spray; Afrin Original 12 Hour Nasal Spray; Afrin Original 12 Hour Nose Drops; Afrin Original 12 Hour Pump Mist; Afrin Sinus 12 Hour Nasal Spray; Duramist Plus Up To 12 Hour Nasal Decongestant Spray; Genasal Nasal Spray Up to 12 Hour Relief; H 990; Nasal Relief 12 Hour Nasal Spray; Nostrilla 12 Hour Nasal Decongestant; Vicks Sinex 12 Hour Nasal Spray; Vicks Sinex 12 Hour Ultra Fine Mist for Sinus Relief; Decongestant (TN); Neo-Synephrine 12 Hour Spray; Operil (TN); Oximetazolina [INN-Spanish]; Oxymetazoline (INN); Oxymetazoline [INN:BAN]; Oxymetazolinum [INN-Latin]; Visine L.R; Visine L.R.; Phenol, 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethyl-(7CI,8CI); Phenol, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl-(9CI); 2-(4-tert-Butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline; 3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethyl-6-tert-butyl-phenol; 3-[(4,5-Dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol; 6-t-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol; 6-tert-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol; 6-tert-Butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol

Indication

Disease Entry	ICD 11	Status	REF
Arrhythmia	BC9Z	Approved	[1]
Eye inflammation	9A02	Approved	[2]
Fecal incontinence	ME07	Approved	[1]
Nasal congestion	MD11.9	Approved	[2]

• Therapeutic Class: Nasal Decongestants
• Cross-matching ID:
  PubChem CID: 4636
  ChEBI ID: CHEBI:7862
  CAS Number: CAS 1491-59-4
  TTD Drug ID: DM8ZXT6
  INTEDE Drug ID: DR1224
  ACDINA Drug ID: D01309

Molecule-Related Drug Atlas

Drug(s) Targeting Adrenergic receptor Alpha-2 (ADRA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[8]
Meperidine	DMX4GND	Pain	MG30-MG3Z	Approved	[9]
Lofexidine	DM1WXA6	Heroin and opiate withdrawal	6C43	Approved	[10]
Sodium chloride	DMM3950	Skin burns	ME65.0	Approved	[8]
Guanfacine extended release	DMB1CZ8	Attention deficit hyperactivity disorder	6A05.Z	Approved	[11]
Dexmedetomidine	DM93L4X	Irritability	MB24	Approved	[12]
Yohimbine	DMJCP1Y	Erectile dysfunction	HA01.1	Approved	[13]
Guanabenz	DM5QWEL	High blood pressure	BA00	Approved	[14]
Tizanidine	DMR2IQ4	Spasm	MB47.3	Approved	[15]
Brimonidine	DMQLT4N	Ocular hypertension	9C61.01	Approved	[16]

Drug(s) Metabolized By UDP-glucuronosyltransferase 1A1 (UGT1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[17]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[18]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[19]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[20]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[21]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[22]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[23]
Metronidazole	DMTIVEN	Abscess		Approved	[24]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[25]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[26]

Drug(s) Affected By Alpha-2A adrenergic receptor (ADRA2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[27]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[28]
Rilmenidine	DM13PQW	Hypertension	BA00-BA04	Approved	[29]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[30]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[31]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[32]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[33]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[34]
Indapamide	DMGN1PW	Edema	MG29	Approved	[35]
Niclosamide	DMJAGXQ	Cestodes infection	1F70-1F76	Approved	[36]

Drug(s) Affected By Alpha-2C adrenergic receptor (ADRA2C)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[37]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[38]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[34]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[39]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[40]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[41]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[42]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[43]
Xylometazoline	DMKV32D	Allergic rhinitis	CA08.0	Phase 4	[6]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[44]

Drug(s) Affected By Alpha-1B adrenergic receptor (ADRA1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[45]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[46]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[38]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[47]
Terbutaline	DMD4381	Asthma	CA23	Approved	[48]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[45]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[48]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[49]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[50]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[51]

Drug(s) Affected By Alpha-1D adrenergic receptor (ADRA1D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alfuzosin	DMZVMKF	Benign prostatic hyperplasia	GA90	Approved	[52]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[45]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[46]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[34]
Terbutaline	DMD4381	Asthma	CA23	Approved	[48]
Methoxamine	DMF5XQH	Hypertension	BA00-BA04	Approved	[7]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[45]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[48]
Norepinephrine	DMOUC09	Alopecia	ED70	Approved	[7]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[53]

Drug(s) Affected By Alpha-1A adrenergic receptor (ADRA1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tamsulosin	DM5QF9V	Benign prostatic hyperplasia	GA90	Approved	[5]
SILODOSIN	DMJSBT6	Benign prostatic hyperplasia	GA90	Approved	[46]
Gabapentin	DM6T924	Complex partial seizure	8A68.0	Approved	[28]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[45]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[46]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[54]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[55]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[45]
Norepinephrine	DMOUC09	Alopecia	ED70	Approved	[52]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[56]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor Alpha-2 (ADRA2)	TTQ8AFT	NOUNIPROTAC	Agonist	[3]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
UDP-glucuronosyltransferase 1A1 (UGT1A1) Main DME	DEYGVN4	UD11_HUMAN	Substrate	[4]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Alpha-1A adrenergic receptor (ADRA1A)	OTUIWCL5	ADA1A_HUMAN	Protein Interaction/Cellular Processes	[5]
Alpha-1B adrenergic receptor (ADRA1B)	OTSAYAFD	ADA1B_HUMAN	Protein Interaction/Cellular Processes	[6]
Alpha-1D adrenergic receptor (ADRA1D)	OTW2CD1O	ADA1D_HUMAN	Protein Interaction/Cellular Processes	[7]
Alpha-2A adrenergic receptor (ADRA2A)	OTZFGOTP	ADA2A_HUMAN	Protein Interaction/Cellular Processes	[6]
Alpha-2C adrenergic receptor (ADRA2C)	OT5B9RKP	ADA2C_HUMAN	Protein Interaction/Cellular Processes	[6]

References

• [1] Oxymetazoline FDA Label
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2049-55.
• [4] Identification and characterization of oxymetazoline glucuronidation in human liver microsomes: evidence for the involvement of UGT1A9. J Pharm Sci. 2011 Feb;100(2):784-93.
• [5] Cell membrane chromatography competitive binding analysis for characterization of 1A adrenoreceptor binding interactions. Anal Bioanal Chem. 2011 Jul;400(10):3625-33. doi: 10.1007/s00216-011-5026-z. Epub 2011 May 5.
• [6] Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39.
• [7] Chromatography studies on bio-affinity of nine ligands of alpha1-adrenoceptor to alpha1D subtypes overexpressed in cell membrane. Sci China C Life Sci. 2004 Aug;47(4):376-81. doi: 10.1360/03yc0109.
• [8] Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav. 2000 Nov;67(3):397-403.
• [9] Meperidine, remifentanil and tramadol but not sufentanil interact with alpha(2)-adrenoceptors in alpha(2A)-, alpha(2B)- and alpha(2C)-adrenoceptor ... Eur J Pharmacol. 2008 Mar 17;582(1-3):70-7.
• [10] Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis. Am J DrugAlcohol Abuse. 2008;34(5):611-6.
• [11] Emerging drugs for attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34.
• [12] Dexmedetomidine in intensive care unit: a study of hemodynamic changes. Middle East J Anesthesiol. 2002 Oct;16(6):587-95.
• [13] Acute neurotoxicity after yohimbine ingestion by a body builder. Clin Toxicol (Phila). 2009 Sep;47(8):827-9.
• [14] Centrally acting sympathetic inhibitors for therapy of patients with hypertension. Nippon Rinsho. 1997 Aug;55(8):2081-5.
• [15] Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997 Mar;53(3):435-52.
• [16] Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum. 2000 Aug;43(8):1886-90.
• [17] Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
• [18] Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
• [19] Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
• [20] UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
• [21] Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
• [22] Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
• [23] Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
• [24] Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
• [25] Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
• [26] Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
• [27] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [28] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [29] Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice. Br J Pharmacol. 1999 Mar;126(6):1522-30. doi: 10.1038/sj.bjp.0702429.
• [30] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [31] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [32] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [33] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [34] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [35] Platelet alpha 2-adrenoceptor modifications induced by long-term treatment with indapamide in essential hypertension. Am J Med. 1988 Jan 29;84(1B):31-5.
• [36] Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
• [37] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [38] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [39] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [40] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [41] Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
• [42] Unique transcriptome, pathways, and networks in the human endometrial fibroblast response to progesterone in endometriosis. Biol Reprod. 2011 Apr;84(4):801-15.
• [43] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [44] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [45] Effects of quinidine and verapamil on human cardiovascular alpha1-adrenoceptors. Circulation. 1998 Apr 7;97(13):1227-30. doi: 10.1161/01.cir.97.13.1227.
• [46] Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. Cardiovasc Res. 2004 Sep 1;63(4):662-72. doi: 10.1016/j.cardiores.2004.05.014.
• [47] Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
• [48] Neuroendocrine mediators up-regulate alpha1b- and alpha1d-adrenergic receptor subtypes in human monocytes. J Neuroimmunol. 1999 Mar 1;95(1-2):165-73. doi: 10.1016/s0165-5728(99)00011-9.
• [49] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [50] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [51] Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
• [52] The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994 Apr;45(4):703-8.
• [53] Epigenetic regulation of human alpha1d-adrenergic receptor gene expression: a role for DNA methylation in Sp1-dependent regulation. FASEB J. 2007 Jul;21(9):1979-93. doi: 10.1096/fj.06-7118com. Epub 2007 Mar 23.
• [54] Adipogenic Effects and Gene Expression Profiling of Firemaster? 550 Components in Human Primary Preadipocytes. Environ Health Perspect. 2017 Sep 14;125(9):097013. doi: 10.1289/EHP1318.
• [55] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [56] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.